{"ctNumber":"2024-513248-27-00","ctStatus":"Authorised","startDateEU":"2020-07-20","decisionDate":"2024-06-17T17:55:31.466","publishDate":"2026-09-16T03:32:36.84824089","ctPublicStatusCode":5,"authorizedApplication":{"authorizedPartI":{"id":86598,"rowSubjectCount":0,"products":[{"id":355647,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"10639235","productPharmForm":"SOLUTION FOR INFUSION","euMpNumber":"PRD8848399","marketingAuthNumber":"EU/1/01/176/007","prodAuthStatus":2,"prodName":"Zometa 4 mg/100 ml solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"ZOLEDRONIC ACID MONOHYDRATE","euSubstNumber":"SUB21645","authorisationCountryCode":"NO","mrpNumber":"EMEA/H/C/000336","nameOrg":"PHOENIX LABS UNLIMITED COMPANY","productSubstances":[{"productPk":"10639235","substancePk":"328364","nameOrg":"PHOENIX LABS UNLIMITED COMPANY","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"ZOLEDRONIC ACID MONOHYDRATE","substanceEvCode":"SUB21645"}],"atcCode":"M05BA08","atcName":"ZOLEDRONIC ACID","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"4","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"52","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"chemical","evCode":"PRD8848399","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":true,"productName":"Zometa 4 mg/100 ml solution for infusion","jsonActiveSubstanceNames":"zoledronic acid monohydrate","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":355648,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11168501","productPharmForm":"SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE","euMpNumber":"PRD11163510","marketingAuthNumber":"EU/1/11/703/004","prodAuthStatus":2,"prodName":"XGEVA 120 mg solution for injection in pre-filled syringe","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"DENOSUMAB","euSubstNumber":"SUB29173","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/002173","nameOrg":"AMGEN EUROPE B.V.","productSubstances":[{"productPk":"11168501","substancePk":"368670","nameOrg":"AMGEN EUROPE B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"DENOSUMAB","substanceEvCode":"SUB29173","synonyms":["AMG 162","HLX14","TVB-009","MAB-22"]}],"atcCode":"M05BX04","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"120","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"120","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","evCode":"PRD11163510","devices":[],"characteristics":[],"routes":["SUBCUTANEOUS INJECTION"],"allSubstancesChemicals":false,"productName":"XGEVA 120 mg solution for injection in pre-filled syringe","jsonActiveSubstanceNames":"denosumab","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"Multicentre, randomized, controlled, open-label, multi-centre medicoeconomic study evaluating the efficacy of adding zoledronic acid or denosumab to Stereotaxic radiotherapy in the treatment of vertebral metastases (ZOSTER)","fullTitleTranslations":[{"id":6600790,"uuid":"5c1c41e7-9b71-4d5e-8c8f-9e78397678de","attributeTranslation":"Etude médico-économique multicentrique de phase III, randomisée, contrôlée, en ouvert, évaluant l’efficacité de l’ajout de l’acide Zolédronique ou du denOsumab à la radiothérapie STERéotaxique dans le traitement des métastases vertébrales","language":10,"languageDescription":"French"}],"publicTitle":"Multicentre, randomized, controlled, open-label, multi-centre medicoeconomic study evaluating the efficacy of adding zoledronic acid or denosumab to Stereotaxic radiotherapy in the treatment of vertebral metastases (ZOSTER)","publicTitleTranslations":[{"id":6600799,"uuid":"87894f4e-25f7-4a54-baa5-4b712bb09075","attributeTranslation":"Etude médico-économique multicentrique de phase III, randomisée, contrôlée, en ouvert, évaluant l’efficacité de l’ajout de l’acide Zolédronique ou du denOsumab à la radiothérapie STERéotaxique dans le traitement des métastases vertébrales","language":34,"languageDescription":"French (France)"}],"shortTitle":"ZOSTER ICO-N-2018-14","secondaryIdentifyingNumbers":{"nctNumber":{"id":385500,"number":"NCT03951493"},"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"5","trialCategory":"2","justificationForTrialCategory":"it's a phase III","trialCategoryId":77714},"medicalCondition":{"partIMedicalConditions":[{"id":88765,"medicalCondition":"Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy","medicalConditionTranslations":[{"id":6600764,"uuid":"330d8807-0bf8-419e-bde2-23686bd483fc","attributeTranslation":"Patients, homme ou femme âgés de plus de 18 ans et présentant des métastases vertébrales osseuses inopérables justifiant un traitement par radiothérapie stéréotaxique","language":10,"languageDescription":"French"}],"isConditionRareDisease":false}],"meddraConditionTerms":[{"termId":100000062212,"version":"21.1","level":"LLT","termName":"Metastatic bone pain","classificationCode":"10049038","organClass":10029104,"active":false},{"termId":100000035197,"version":"20.0","level":"LLT","termName":"Metastatic","classificationCode":"10027474","organClass":10029104,"active":false},{"termId":100000020832,"version":"21.1","level":"LLT","termName":"Metastatic pain","classificationCode":"10027484","organClass":10029104,"active":false}]},"trialObjective":{"trialScopes":[{"code":"12","trialScopeId":256846},{"code":"3","trialScopeId":256844},{"code":"5","trialScopeId":256845}],"mainObjective":"to evaluate, on the basis of a cost-utility analysis and a randomised phase 3 study, the efficacy of adding zoledronic acid or denosumab to stereotactic radiotherapy in the treatment of vertebral metastases","mainObjectiveTranslations":[{"id":6600798,"uuid":"17e8974d-eb2e-4bfb-89a5-33e56c661995","attributeTranslation":"Evaluer, à partir d’une analyse coût-utilité et sur la base d’une étude randomisée de phase 3, l’efficience de l’ajout de l’acide zolédronique ou du denosumab à la radiothérapie stéréotaxique dans le traitement des métastases vertébrales","language":34,"languageDescription":"French (France)"}],"secondaryObjectives":[{"id":292736,"number":1,"secondaryObjective":"Cost-effectiveness analysis","secondaryObjectiveTranslations":[{"id":6600800,"uuid":"e4b75204-ad42-43d9-bf49-510bb9cc902a","attributeTranslation":"Analyse coût-efficacité","language":34,"languageDescription":"French (France)"}]},{"id":292737,"number":2,"secondaryObjective":"Budget impact analysis","secondaryObjectiveTranslations":[{"id":6600801,"uuid":"83c56e6a-86f4-433f-a976-a704f75e46cf","attributeTranslation":"Analyse d’impact budgétaire","language":34,"languageDescription":"French (France)"}]},{"id":292738,"number":3,"secondaryObjective":"Determination of vertebral compression fracture-free survival (vertebral compression)","secondaryObjectiveTranslations":[{"id":6600802,"uuid":"81bc7206-2bf3-45cc-8815-682f93118a98","attributeTranslation":"Détermination de la survie sans fracture compressive vertébrale (tassement vertébral)","language":34,"languageDescription":"French (France)"}]},{"id":292739,"number":4,"secondaryObjective":"Bone complication-free survival (fracture, cementoplasty, bone surgery and spinal cord compression)","secondaryObjectiveTranslations":[{"id":6600803,"uuid":"850d0eef-cef8-41b2-ba06-e49e296cea6c","attributeTranslation":"Survie sans complication osseuse (fracture, cimentoplastie, chirurgie osseuse et compression médullaire)","language":34,"languageDescription":"French (France)"}]},{"id":292740,"number":5,"secondaryObjective":"Assessment of toxicity;","secondaryObjectiveTranslations":[{"id":6600804,"uuid":"a1b39953-c342-41c4-a469-3b3146eae6fe","attributeTranslation":"Evaluation des toxicités","language":34,"languageDescription":"French (France)"}]},{"id":292741,"number":6,"secondaryObjective":"Assessment of pain control","secondaryObjectiveTranslations":[{"id":6600805,"uuid":"917349f6-e8d1-46cf-aa6e-17b460d9138c","attributeTranslation":"Evaluation du contrôle de la douleur","language":34,"languageDescription":"French (France)"}]},{"id":292742,"number":7,"secondaryObjective":"Assessment of local control of irradiated tumour lesions","secondaryObjectiveTranslations":[{"id":6600806,"uuid":"c5bcdda7-b1b9-46a6-8461-0e9e29c1039e","attributeTranslation":"Evaluation du contrôle local des lésions tumorales irradiées","language":34,"languageDescription":"French (France)"}]},{"id":292743,"number":8,"secondaryObjective":"Assessment of neoplastic spinal instability","secondaryObjectiveTranslations":[{"id":6600807,"uuid":"223170f3-7568-4cc5-a6d5-16d51b406f06","attributeTranslation":"Evaluation de l’instabilité rachidienne néoplasique","language":34,"languageDescription":"French (France)"}]},{"id":292744,"number":9,"secondaryObjective":"Assessment of bone density","secondaryObjectiveTranslations":[{"id":6600808,"uuid":"3223532d-f4c3-4ad5-b9c9-e684da5727e5","attributeTranslation":"Évaluation de la densité osseuse","language":34,"languageDescription":"French (France)"}]},{"id":292745,"number":10,"secondaryObjective":"Biological collection to determine a profile of immunological response and markers of bone remodelling after hypofractionated radiotherapy under stereotactic conditions and determination of the impact of zoledronic acid or denosumab on these biomarkers.","secondaryObjectiveTranslations":[{"id":6600809,"uuid":"dc667e5e-58f1-4c54-b461-01d386b0d216","attributeTranslation":"Collection biologique visant à déterminer un profil de réponse immunologique et de marqueurs du remodelage osseux après radiothérapie hypofractionnée en conditions stéréotaxiques et détermination de l’impact de l’acide zolédronique ou du denosumab sur ces biomarqueurs","language":34,"languageDescription":"French (France)"}]},{"id":292746,"number":11,"secondaryObjective":"Determination by deep learning of a predictive model for the occurrence of a bone fracture at 1 year based on imaging examinations.","secondaryObjectiveTranslations":[{"id":6600810,"uuid":"877a9f72-5a76-4e25-89f8-7c6f30322aba","attributeTranslation":"Détermination par apprentissage profond d'un modèle prédictif de survenue d'une fracture osseuse à 1 an à partir d'examens d'imageries","language":34,"languageDescription":"French (France)"}]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":565007,"number":1,"principalInclusionCriteria":"Cancer with inoperable thoracic and/or lumbar vertebral metastases","principalInclusionCriteriaTranslations":[{"id":6600791,"uuid":"8ebd4b3c-8859-4375-bd5d-9b16154a36e1","attributeTranslation":"Cancer avec métastase vertébrale thoracique et/ou lombaire inopérable","language":34,"languageDescription":"French (France)"}]},{"id":565008,"number":2,"principalInclusionCriteria":"Age ≥ 18 years","principalInclusionCriteriaTranslations":[{"id":6600792,"uuid":"587c264d-21ff-42a5-8e23-764a0e3c4a23","attributeTranslation":"Age ≥ 18 ans","language":34,"languageDescription":"French (France)"}]},{"id":565009,"number":3,"principalInclusionCriteria":"Life expectancy greater than 1 year","principalInclusionCriteriaTranslations":[{"id":6600793,"uuid":"8cb18abd-9b0d-408e-9740-083c3ed1691d","attributeTranslation":"Espérance de vie supérieure à 1 an","language":34,"languageDescription":"French (France)"}]},{"id":565010,"number":4,"principalInclusionCriteria":"WHO or PS ≤ 2","principalInclusionCriteriaTranslations":[{"id":6600794,"uuid":"b5ead99b-d79f-4beb-b76d-8acf5fa6ff94","attributeTranslation":"OMS ou PS ≤ 2","language":34,"languageDescription":"French (France)"}]},{"id":565011,"number":5,"principalInclusionCriteria":"Effective contraception for women of childbearing age","principalInclusionCriteriaTranslations":[{"id":6600795,"uuid":"cd8fcf27-6640-40da-9a56-570270919755","attributeTranslation":"Contraception efficace pour les femmes en âge de procréer","language":34,"languageDescription":"French (France)"}]},{"id":565012,"number":6,"principalInclusionCriteria":"Informing the patient and obtaining free, informed and written consent, signed by the patient and the investigator","principalInclusionCriteriaTranslations":[{"id":6600796,"uuid":"b84190dc-b1fd-4484-9029-424f14d9c688","attributeTranslation":"Information du/de la patient(e) et obtention du consentement libre, éclairé et écrit, signé par le/la patient(e) et l’investigateur","language":34,"languageDescription":"French (France)"}]},{"id":565013,"number":7,"principalInclusionCriteria":"Patient affiliated to or benefiting from the social security system","principalInclusionCriteriaTranslations":[{"id":6600797,"uuid":"75a99793-b7fa-4f08-8755-a61fe4fef2f5","attributeTranslation":"Patient(e) affilié(e) ou bénéficiaire du régime de sécurité sociale","language":34,"languageDescription":"French (France)"}]}],"principalExclusionCriteria":[{"id":971936,"number":1,"principalExclusionCriteria":"Painful patient unable to maintain a supine position for 30 minutes despite analgesic treatment;","principalExclusionCriteriaTranslations":[{"id":6600777,"uuid":"d228d20a-6bc6-4253-93bc-54d5f023b47c","attributeTranslation":"Patient(e) douloureux incapable de maintenir une position couchée pendant 30 minutes malgré un traitement antalgique","language":34,"languageDescription":"French (France)"}]},{"id":971937,"number":10,"principalExclusionCriteria":"Patient under guardianship or unable to give consent;","principalExclusionCriteriaTranslations":[{"id":6600778,"uuid":"85a0fce0-3942-4348-84e4-a753aabb8717","attributeTranslation":"Patient(e) protégé(e) ou sous tutelle ou incapable de donner son consentement","language":34,"languageDescription":"French (France)"}]},{"id":971938,"number":11,"principalExclusionCriteria":"Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.","principalExclusionCriteriaTranslations":[{"id":6600779,"uuid":"423e67df-5f2a-4f41-89a3-6b0f2c20482c","attributeTranslation":"Impossibilité de se soumettre au suivi médical de l’essai pour des raisons géographiques, sociales ou psychiques","language":34,"languageDescription":"French (France)"}]},{"id":971939,"number":12,"principalExclusionCriteria":"Previous treatment with desonumab within the last 6 months or ongoing at inclusion.","principalExclusionCriteriaTranslations":[{"id":6600780,"uuid":"387ba31a-8809-4efc-bd07-6d7177e91d23","attributeTranslation":"Traitement antérieur par desonumab au cours des 6 derniers mois ou en cours à l’inclusion","language":34,"languageDescription":"French (France)"}]},{"id":971940,"number":13,"principalExclusionCriteria":"Patients with severe untreated hypocalcaemia.","principalExclusionCriteriaTranslations":[{"id":6600781,"uuid":"46f1b134-dfb9-4732-954e-e902f5928260","attributeTranslation":"Patients souffrant d'hypocalcémie sévère non traitée","language":34,"languageDescription":"French (France)"}]},{"id":971941,"number":2,"principalExclusionCriteria":"suppressed","principalExclusionCriteriaTranslations":[{"id":6600782,"uuid":"1fd809dc-f6b1-44da-9f07-5f41fc80fb8f","attributeTranslation":"Critère supprimé MS1 18.02.2021 : Patient(e) ayant reçu une irradiation externe de la zone d'irradiation proposée > 20 Gy","language":34,"languageDescription":"French (France)"}]},{"id":971942,"number":3,"principalExclusionCriteria":"Signs of neurological compression","principalExclusionCriteriaTranslations":[{"id":6600783,"uuid":"e6abcf3d-1f2d-469c-98aa-b3838546570b","attributeTranslation":"Signes de compression neurologique","language":33,"languageDescription":"French (Belgium)"}]},{"id":971943,"number":4,"principalExclusionCriteria":"Spinal cord compression or epidural involvement requiring surgery prior to radiotherapy;","principalExclusionCriteriaTranslations":[{"id":6600784,"uuid":"45fcde29-25bc-4653-a197-11f10c77f998","attributeTranslation":"Compression de la moelle épinière ou atteinte épidurale nécessitant une intervention chirurgicale avant une radiothérapie","language":34,"languageDescription":"French (France)"}]},{"id":971944,"number":5,"principalExclusionCriteria":"Clinically significant hypersensitivity to zoledronic acid or denosumab, other bisphosphonates or any excipient;","principalExclusionCriteriaTranslations":[{"id":6600785,"uuid":"a317d90a-8ca9-4035-baf3-02cff0859835","attributeTranslation":"Hypersensibilité cliniquement significative à l’acide zolédronique ou au denosumab, à d'autres bisphosphonates ou à tout excipient","language":34,"languageDescription":"French (France)"}]},{"id":971945,"number":6,"principalExclusionCriteria":"A history of osteonecrosis of the jawbone or exposed bone or delayed healing after dental surgery;","principalExclusionCriteriaTranslations":[{"id":6600786,"uuid":"f2c659a6-b3df-44d0-949d-ea02a521bb7e","attributeTranslation":"Antécédent d'ostéonécrose du maxillaire ou de mise à nu de l'os ou de retard de cicatrisation après une intervention dentaire","language":34,"languageDescription":"French (France)"}]},{"id":971946,"number":7,"principalExclusionCriteria":"Previous bisphosphonate treatment within the last 24 months or ongoing at inclusion;","principalExclusionCriteriaTranslations":[{"id":6600787,"uuid":"e36317c7-cf1c-4478-96d7-74938aa08106","attributeTranslation":"Traitement antérieur par bisphosphonate au cours des 24 derniers mois ou en cours à l’inclusion","language":34,"languageDescription":"French (France)"}]},{"id":971947,"number":8,"principalExclusionCriteria":"Creatinine clearance < 30 ml/min;","principalExclusionCriteriaTranslations":[{"id":6600788,"uuid":"dadebd6b-a64a-40bf-83d2-28aed100058b","attributeTranslation":"Clairance de la créatinine < 30 ml/min","language":34,"languageDescription":"French (France)"}]},{"id":971948,"number":9,"principalExclusionCriteria":"Pregnant or breast-feeding woman;","principalExclusionCriteriaTranslations":[{"id":6600789,"uuid":"8e42dcd5-2739-46f0-817e-ff9be32e26df","attributeTranslation":"Femme enceinte ou allaitante","language":34,"languageDescription":"French (France)"}]}]},"endPoint":{"primaryEndPoints":[{"id":659535,"number":1,"endPoint":"of life gained in good health. Calculating the ICER requires :  - Identifying care consumption; - Measuring costs;  - Estimating overall survival; - Calculating utilities using the EQ5D-5L questionnaire (appendix 11).  The ROCR will be measured at 6 months and 24 months after the start of radiotherapy.","isPrimary":true,"endPointTranslations":[{"id":6600765,"uuid":"db03b840-40e6-4217-8b6e-86b03b2759d7","attributeTranslation":"Ratio Différentiel Cout Résultat (RDCR) exprimé en coût par année de vie gagnée en bonne santé.Le calcul du RDCR requiert :\n\n-\tL’identification des consommations de soins ;\n-\tLa mesure des coûts ; \n-\tL’estimation de la survie globale ;\n-\tLe calcul des utilités à l’aide du questionnaire EQ5D-5L (annexe 11).\n\nLe RDCR sera mesuré à 6 mois et à 24 mois du début de la radiothérapie","language":34,"languageDescription":"French (France)"}]}],"secondaryEndPoints":[{"id":659536,"number":1,"endPoint":"Cost-effectiveness analysis: calculation of a Differential Cost Outcome Ratio (DCOER) expressed as a cost per life-year gained measured at 6 months and 24 months from the start of radiotherapy;","isPrimary":false,"endPointTranslations":[{"id":6600766,"uuid":"ba1c1080-e893-44fd-b21d-a591b5a21fc5","attributeTranslation":"Analyse coût-efficacité : calcul d’un Ratio Différentiel Cout Résultat (RDCR) exprimé en coût par année de vie gagnée mesuré à 6 mois et 24 mois du début de la radiothérapie","language":34,"languageDescription":"French (France)"}]},{"id":659537,"number":2,"endPoint":"Budget impact analysis: estimation of the target and reached populations, calculation of the additional costs and avoided costs generated by the diffusion of the innovation in the French healthcare system.","isPrimary":false,"endPointTranslations":[{"id":6600767,"uuid":"a325a584-5d12-4a30-ac8c-679ee9e6b179","attributeTranslation":"Analyse d’impact budgétaire : estimation des populations cible et rejointe, calcul des surcoûts et des coûts évités engendrés par la diffusion de l’innovation dans le système de santé français","language":34,"languageDescription":"French (France)"}]},{"id":659538,"number":3,"endPoint":"Survival without CVF (vertebral compression fractures) estimated at 6, 12 and 24 months.","isPrimary":false,"endPointTranslations":[{"id":6600768,"uuid":"90d6eb5f-337b-4171-83b1-962762de6a6b","attributeTranslation":"Survie sans FCV (fractures compressives vertébrales) estimée à 6, 12 et 24 mois","language":34,"languageDescription":"French (France)"}]},{"id":659539,"number":4,"endPoint":"Survival without bone complications estimated at 6, 12 and 24 months","isPrimary":false,"endPointTranslations":[{"id":6600769,"uuid":"cc2fb716-cd2c-4353-ba74-36189571ec22","attributeTranslation":"Survie sans complication osseuse estimée à 6, 12 et 24 mois","language":34,"languageDescription":"French (France)"}]},{"id":659540,"number":5,"endPoint":"Acute and delayed toxicity: according to CTCAE 5 ;","isPrimary":false,"endPointTranslations":[{"id":6600770,"uuid":"af1c6864-02fe-4d15-9268-5a5b6c1461d7","attributeTranslation":"Toxicité aigüe et retardée : selon CTCAE 5","language":34,"languageDescription":"French (France)"}]},{"id":659541,"number":6,"endPoint":"Pain control: VAS and BPI (appendix 12) assessed at inclusion, 6, 12 and 24 months;","isPrimary":false,"endPointTranslations":[{"id":6600771,"uuid":"bc5ae2ed-9c24-4f5b-8537-d7664da710d2","attributeTranslation":"Contrôle de la douleur : EVA et BPI (annexe 12) évalués à l’inclusion, 6, 12 et 24 mois","language":34,"languageDescription":"French (France)"}]},{"id":659542,"number":7,"endPoint":"Local control of irradiated tumour lesions: MRI and TAP and/or PET scan (quarterly monitoring or in the event of neurological signs) assessed at 6 and 12 months;","isPrimary":false,"endPointTranslations":[{"id":6600772,"uuid":"69c53e80-cea3-4f43-9fd1-70bf63531e0f","attributeTranslation":"Contrôle local des lésions tumorales irradiées : IRM et scanner TAP et/ou TEP (surveillance trimestrielle ou en cas de signe neurologique) évaluée à 6 et 12 mois","language":34,"languageDescription":"French (France)"}]},{"id":659543,"number":8,"endPoint":"Neoplastic Spinal Instability Score (NSSI) assessed at inclusion, 6 and 12 months","isPrimary":false,"endPointTranslations":[{"id":6600773,"uuid":"c5fafa07-69af-4e9f-86db-b5482e8ba817","attributeTranslation":"Score d’instabilité rachidienne néoplasique (SINS) évalué à l’inclusion, à 6 et à 12 mois\nCe score est noté sur 18 points et comprend six paramètres : localisation, douleur osseuse, alignement, ostéolyse, effondrement du corps vertébral et implication des éléments vertébraux postérolatéraux.\nLes lésions seront alors classées ainsi : \n-\tScore total entre 0 et 6 : stable\n-\tScore total entre 7 et 12 : instabilité indéterminée\n-\tScore total entre 13 et 18 : instabilité\n-\tScore total entre 7 et 18","language":34,"languageDescription":"French (France)"}]},{"id":659544,"number":9,"endPoint":"Assessment of bone density: bone densitometry at inclusion, 6 and 12 months;","isPrimary":false,"endPointTranslations":[{"id":6600774,"uuid":"fc064cad-ef73-4b54-acb2-2a130016ac97","attributeTranslation":"Évaluation de la densité osseuse : ostéodensitométrie à l’inclusion, 6 et 12 mois","language":34,"languageDescription":"French (France)"}]},{"id":659545,"number":10,"endPoint":"Measurement of markers of immune response and bone remodelling;","isPrimary":false,"endPointTranslations":[{"id":6600775,"uuid":"cdc22aeb-8d83-4d09-a918-43252d855eef","attributeTranslation":"Dosage de marqueurs de la réponse immunitaire et du remodelage osseux","language":34,"languageDescription":"French (France)"}]},{"id":659546,"number":11,"endPoint":"Sensitivity and specificity of the algorithm for detecting the risk of fracture at 1 year.","isPrimary":false,"endPointTranslations":[{"id":6600776,"uuid":"b029f159-2ccf-4d4a-8206-7548511403ea","attributeTranslation":"Sensibilité et spécificité de l’algorithme pour la détection du risque de fracture à 1 an","language":34,"languageDescription":"French (France)"}]}]},"trialDuration":{"estimatedEndDate":"2027-06-23","estimatedRecruitmentStartDate":"2020-06-23"},"sourceOfMonetarySupport":[{"id":62229,"organisationName":"INCA (AAP DOM)"},{"id":62230,"organisationName":"DGOS Inca PRME 2017 (PRME17-0118)"}],"populationOfTrialSubjects":{"ageRanges":[{"id":235834,"ageRangeCategoryCode":"3","ageRangeCategory":"3"},{"id":235835,"ageRangeCategoryCode":"4","ageRangeCategory":"4"}],"ageRangeSecondaryIds":[],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":false},"individualParticipantData":{"planToShareIPD":"2"}},"protocolInformation":{"studyDesign":{"periodDetails":[{"id":127227,"businessKey":"1","title":"Randomisation and treatment","description":"RSHF +/- Acide zolédronique ou Denosumab","blindingMethodCode":"3","blindedRoles":[],"armDetails":[{"description":"RSHF + Acide zolédronique ou denosumab","title":"A","id":71676},{"description":"RSHF","title":"B","id":71677}],"allocationMethod":"1"}]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-08-18","conclusionDate":"2025-08-18","therapeuticAreas":[{"code":"4","name":"Diseases [C] - Neoplasms [C04]"}],"medicalConditions":[{"id":88765,"medicalCondition":"Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy","isConditionRareDisease":false}],"sponsors":[{"id":94745,"primary":true,"publicContacts":[{"id":283003,"type":"Public","functionalName":"Emilie DEBEAUPUIS","functionalEmailAddress":"emilie.debeaupuis@ico.unicancer.fr","telephone":"+33240679844","organisation":{"id":425993,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Institut De Cancerologie De L Ouest","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100010298","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":283004,"type":"Scientific","functionalName":"Stéphane SUPIOT","functionalEmailAddress":"stephane.supiot@ico.unicancer.fr","telephone":"+33240679900","organisation":{"id":425993,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Institut De Cancerologie De L Ouest","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100010298","organisationLocationStatus":"Active"}}],"thirdParties":[],"organisation":{"id":425993,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Institut De Cancerologie De L Ouest","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100010298","organisationLocationStatus":"Active"},"addresses":[{"id":395137,"organisation":{"id":425993,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Institut De Cancerologie De L Ouest","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100010298","organisationLocationStatus":"Active"},"address":{"addressId":422397,"oneLine":"Bd Du Professeur Jacques Monod","addressLine1":"Bd Du Professeur Jacques Monod","addressLine2":"","addressLine3":"","addressLine4":"","city":"St Herblain","postcode":"44800","country":2012,"countryName":"France"},"isBusinessKeyValidated":true,"businessKey":"ORG-100010298"}],"isCommercial":false,"commercial":"Non-Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"it's a phase III","partOneTherapeuticAreas":[{"id":865933,"therapeuticArea":{"code":"4","name":"Diseases [C] - Neoplasms [C04]"}}],"productRoleGroupInfos":[{"id":269627,"comments":"Zometa 4 mg/100 ml solution for infusion","productRoleCode":"1","productRoleName":"Test","products":[{"id":355647,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"10639235","productPharmForm":"SOLUTION FOR INFUSION","euMpNumber":"PRD8848399","marketingAuthNumber":"EU/1/01/176/007","prodAuthStatus":2,"prodName":"Zometa 4 mg/100 ml solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"ZOLEDRONIC ACID MONOHYDRATE","euSubstNumber":"SUB21645","authorisationCountryCode":"NO","mrpNumber":"EMEA/H/C/000336","nameOrg":"PHOENIX LABS UNLIMITED COMPANY","productSubstances":[{"productPk":"10639235","substancePk":"328364","nameOrg":"PHOENIX LABS UNLIMITED COMPANY","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"ZOLEDRONIC ACID MONOHYDRATE","substanceEvCode":"SUB21645"}],"atcCode":"M05BA08","atcName":"ZOLEDRONIC ACID","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"4","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"52","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"chemical","evCode":"PRD8848399","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":true,"productName":"Zometa 4 mg/100 ml solution for infusion","jsonActiveSubstanceNames":"zoledronic acid monohydrate","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"}]},{"id":269628,"comments":"XGEVA 120 mg solution for injection in pre-filled syringe","productRoleCode":"1","productRoleName":"Test","products":[{"id":355648,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11168501","productPharmForm":"SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE","euMpNumber":"PRD11163510","marketingAuthNumber":"EU/1/11/703/004","prodAuthStatus":2,"prodName":"XGEVA 120 mg solution for injection in pre-filled syringe","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"DENOSUMAB","euSubstNumber":"SUB29173","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/002173","nameOrg":"AMGEN EUROPE B.V.","productSubstances":[{"productPk":"11168501","substancePk":"368670","nameOrg":"AMGEN EUROPE B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"DENOSUMAB","substanceEvCode":"SUB29173","synonyms":["AMG 162","HLX14","TVB-009","MAB-22"]}],"atcCode":"M05BX04","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"120","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"120","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","evCode":"PRD11163510","devices":[],"characteristics":[],"routes":["SUBCUTANEOUS INJECTION"],"allSubstancesChemicals":false,"productName":"XGEVA 120 mg solution for injection in pre-filled syringe","jsonActiveSubstanceNames":"denosumab","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":217328,"mscId":27523,"mscInfo":{"id":27523,"clinicalTrialId":14069,"countryOrganisationId":2012,"reportingStatusCode":"Authorised","fromDate":"2024-05-28","toDate":"2024-05-28","isProposedRms":true,"countryName":"France","organisationInfo":{},"firstDecisionDate":"2024-06-17","trialStatus":"Authorised","trialPeriod":[{"id":25431,"trialStartDate":"2020-07-20","fromDate":"2024-07-08"},{"id":25432,"trialStartDate":"2020-07-20","fromDate":"2024-07-08"}],"trialRecruitmentPeriod":[{"id":31847,"recruitmentStartDate":"2020-07-23","fromDate":"2024-07-08"},{"id":31848,"recruitmentStartDate":"2020-07-23","fromDate":"2024-07-08"},{"id":122432,"recruitmentStartDate":"2020-07-23","recruitmentEndDate":"2026-06-23","fromDate":"2026-09-15"},{"id":122433,"recruitmentStartDate":"2020-07-23","recruitmentEndDate":"2026-06-23","fromDate":"2026-09-15"},{"id":122431,"recruitmentStartDate":"2020-07-23","recruitmentEndDate":"2026-06-23","fromDate":"2026-09-15"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":33654,"trialStartDate":"2020-07-20","fromDate":"2024-07-08"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2020-07-23","recruitmentEndDate":"2026-06-23"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":39452,"mscId":27523,"trialStatus":"Authorised","trialStatusDate":"2024-06-17T17:55:31.077"},{"id":31348,"mscId":27523,"trialStatus":"Under evaluation","trialStatusDate":"2024-04-22T17:04:11.014"}],"applicationTypeMsc":"1","mscName":"France","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-07-04","decision":"authorized","decisionDate":"2024-06-17"},"decisionDate":"2024-06-17","recruitmentSubjectCount":202,"trialSites":[{"id":1452237,"organisationAddressInfo":{"id":395289,"organisation":{"id":426145,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Institut De Cancerologie De L Ouest","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100010298","organisationLocationStatus":"Active"},"address":{"addressId":422562,"oneLine":"Bd Du Professeur Jacques Monod","addressLine1":"Bd Du Professeur Jacques Monod","addressLine2":"","addressLine3":"","addressLine4":"","city":"St Herblain","postcode":"44800","country":2012,"countryName":"France"},"phone":"0","email":"stephane.supiot@ico.unicancer.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100010298"},"personInfo":{"id":1616928,"firstName":"Stéphane","lastName":"SUPIOT","telephone":"0","email":"stephane.supiot@ico.unicancer.fr"},"departmentName":"Radiotherapy"},{"id":1452236,"organisationAddressInfo":{"id":760122,"organisation":{"id":798790,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Regional Et Universitaire De Brest","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100007294","organisationLocationStatus":"Active"},"address":{"addressId":837647,"oneLine":"Boulevard Tanguy Prigent","addressLine1":"Boulevard Tanguy Prigent","addressLine2":"","addressLine3":"","addressLine4":"","city":"Brest","postcode":"29200","country":2012,"countryName":"France"},"phone":"0","email":"francois.lucia@chu-brest.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100007294"},"personInfo":{"id":1616927,"firstName":"François","lastName":"LUCIA","telephone":"0","email":"francois.lucia@chu-brest.fr"},"departmentName":"Radiotherapy"},{"id":1452234,"organisationAddressInfo":{"id":395334,"organisation":{"id":426191,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"CHU De Martinique","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100044137","organisationLocationStatus":"Active"},"address":{"addressId":422610,"oneLine":"P. O. Box 90632","addressLine1":"P. O. Box 90632","addressLine2":"","addressLine3":"","addressLine4":"","city":"Fort De France Cedex","postcode":"97261","country":2012,"countryName":"France"},"phone":"0","email":"Alexis.vallard@chu-martinique.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100044137"},"personInfo":{"id":1616925,"firstName":"Alexis","lastName":"VALLARD","telephone":"0","email":"Alexis.vallard@chu-martinique.fr"},"departmentName":"Radiotherapy"},{"id":1452232,"organisationAddressInfo":{"id":395321,"organisation":{"id":426178,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Institut De Cancerologie De Lorraine","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100042918","organisationLocationStatus":"Active"},"address":{"addressId":422596,"oneLine":"6 Avenue De Bourgogne","addressLine1":"6 Avenue De Bourgogne","addressLine2":"","addressLine3":"","addressLine4":"","city":"Vandouvre Les Nancy","postcode":"54500","country":2012,"countryName":"France"},"phone":"0","email":"jc.faivre@nancy.unicancer.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100042918"},"personInfo":{"id":1616923,"firstName":"Jean-Christophe","lastName":"FAIVRE","telephone":"0","email":"jc.faivre@nancy.unicancer.fr"},"departmentName":"Radiotherapy"},{"id":1452231,"organisationAddressInfo":{"id":395294,"organisation":{"id":426151,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Institut De Cancerologie De L Ouest","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100010298","organisationLocationStatus":"Active"},"address":{"addressId":422568,"oneLine":"15 Rue Andre Boquel","addressLine1":"15 Rue Andre Boquel","addressLine2":"","addressLine3":"","addressLine4":"","city":"Angers","postcode":"49100","country":2012,"countryName":"France"},"phone":"0","email":"stephane.supiot@ico.unicancer.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100010298"},"personInfo":{"id":1616922,"firstName":"Stéphane","lastName":"SUPIOT","telephone":"0","email":"stephane.supiot@ico.unicancer.fr"},"departmentName":"Radiotherapy"},{"id":1452238,"organisationAddressInfo":{"id":395295,"organisation":{"id":426152,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Henri Becquerel","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100029528","organisationLocationStatus":"Active"},"address":{"addressId":422570,"oneLine":"1 Rue D Amiens","addressLine1":"1 Rue D Amiens","addressLine2":"","addressLine3":"","addressLine4":"","city":"Rouen","postcode":"76000","country":2012,"countryName":"France"},"phone":"0","email":"sebastien.thureau@chb.unicancer.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100029528"},"personInfo":{"id":1616929,"firstName":"Sébastien","lastName":"THUREAU","telephone":"0","email":"sebastien.thureau@chb.unicancer.fr"},"departmentName":"Radiotherapy"},{"id":1452241,"organisationAddressInfo":{"id":760124,"organisation":{"id":798792,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Groupe Hospitalier Bretagne Sud","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100043984","organisationLocationStatus":"Active"},"address":{"addressId":837649,"oneLine":"5 Avenue Etienne Francois De Choiseul","addressLine1":"5 Avenue Etienne Francois De Choiseul","addressLine2":"","addressLine3":"","addressLine4":"","city":"Lorient","postcode":"56100","country":2012,"countryName":"France"},"phone":"0","email":"c.berthet@ghbs.bzh","isBusinessKeyValidated":true,"businessKey":"ORG-100043984"},"personInfo":{"id":1616932,"firstName":"Camille","lastName":"BERTHET","telephone":"0","email":"c.berthet@ghbs.bzh","title":"1"},"departmentName":"Radiotherapy"},{"id":1452233,"organisationAddressInfo":{"id":395325,"organisation":{"id":426182,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Clinique Pasteur","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100046819","organisationLocationStatus":"Active"},"address":{"addressId":422600,"oneLine":"45 Avenue De Lombez, Cs 27617","addressLine1":"45 Avenue De Lombez","addressLine2":"Cs 27617","addressLine3":"","addressLine4":"","city":"Toulouse Cedex 3","postcode":"31076","country":2012,"countryName":"France"},"phone":"0","email":"ilatorzeff@clinique-pasteur.com","isBusinessKeyValidated":true,"businessKey":"ORG-100046819"},"personInfo":{"id":1616924,"firstName":"Igor","lastName":"LATORZEFF","telephone":"0","email":"ilatorzeff@clinique-pasteur.com"},"departmentName":"Radiotherapy"},{"id":1452240,"organisationAddressInfo":{"id":395328,"organisation":{"id":426185,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"L'Hopital Prive Du Confluent","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100041120","organisationLocationStatus":"Active"},"address":{"addressId":422603,"oneLine":"4 Rue Eric Tabarly","addressLine1":"4 Rue Eric Tabarly","addressLine2":"","addressLine3":"","addressLine4":"","city":"Nantes Cedex 2","postcode":"44277","country":2012,"countryName":"France"},"phone":"0","email":"xavier.buthaud@groupeconfluent.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100041120"},"personInfo":{"id":1616931,"firstName":"Xavier","lastName":"BUTHAUD","telephone":"0","email":"xavier.buthaud@groupeconfluent.fr"},"departmentName":"Radiotherapy"},{"id":1452235,"organisationAddressInfo":{"id":395318,"organisation":{"id":426175,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospices Civils De Lyon","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100006597","organisationLocationStatus":"Active"},"address":{"addressId":422593,"oneLine":"3 Quai Des Celestins, Bp 2251","addressLine1":"3 Quai Des Celestins","addressLine2":"Bp 2251","addressLine3":"","addressLine4":"","city":"Lyon Cedex 02","postcode":"69229","country":2012,"countryName":"France"},"phone":"0","email":"ariane.lapierre@chu-lyon.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100006597"},"personInfo":{"id":1616926,"firstName":"Ariane","lastName":"LAPIERRE","telephone":"0","email":"ariane.lapierre@chu-lyon.fr"},"departmentName":"Radiotherapy"},{"id":1452239,"organisationAddressInfo":{"id":395323,"organisation":{"id":426180,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Institut Bergonie","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009865","organisationLocationStatus":"Active"},"address":{"addressId":422598,"oneLine":"180 R De Saint Genes, 229 Cours De L Argonne","addressLine1":"180 R De Saint Genes","addressLine2":"229 Cours De L Argonne","addressLine3":"","addressLine4":"","city":"Bordeaux","postcode":"33000","country":2012,"countryName":"France"},"phone":"0","email":"s.batard@bordeaux.unicancer.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100009865"},"personInfo":{"id":1616930,"firstName":"Stéphanie","lastName":"BATARD","telephone":"0","email":"s.batard@bordeaux.unicancer.fr"},"departmentName":"Radiotherapy"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":23070,"type":"INITIAL","status":"Authorised","ctNumber":"2024-513248-27-00","trialStatus":"Authorised","submissionDate":"2024-04-22","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-05-27"},"partIIInfo":[{"id":96391,"mscId":27523,"mscInfo":{"id":27523,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-06-11","decision":"authorized","decisionDate":"2024-06-17","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2024-06-17"},"applicationStatusCode":"Authorised"}],"decisionDate":"2024-06-17","ctMSCsByApplication":[{"id":27523,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"IN","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":25531,"applicationId":23070,"mscId":27523,"mscName":"France","decisionDate":"2024-06-17T17:55:31.466","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":96391,"part1Id":38376,"applicationType":"INITIAL","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"fa628b2d-504f-40dd-b1d0-491cef774ad5","productRoleGroupId":117397},{"documentUuid":"5d3139b4-0376-4d47-8bbe-1705025cdfbe","productRoleGroupId":117396}]},{"id":55595,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-513248-27-00","trialStatus":"Authorised","submissionDate":"2025-05-16","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-08-18"},"partIIInfo":[{"id":217328,"mscId":27523,"mscInfo":{"id":27523,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-07-04","decision":"authorized","decisionDate":"2024-06-17","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2024-06-17"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-08-22","ctMSCsByApplication":[{"id":27523,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"SM-1","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":85902,"applicationId":55595,"mscId":27523,"mscName":"France","decisionDate":"2025-08-22T13:17:04.856","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":217328,"part1Id":86598,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"fa628b2d-504f-40dd-b1d0-491cef774ad5","productRoleGroupId":269627},{"documentUuid":"5d3139b4-0376-4d47-8bbe-1705025cdfbe","productRoleGroupId":269628}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"France","mscId":27523,"firstDecisionDate":"2024-06-17T17:55:31.466","lastDecisionDate":"2025-08-22T13:17:04.856","mscPublicStatusCode":5}],"eudraCt":{"isTransitioned":true,"eudraCtCode":"2019-001209-26"}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":27523,"mscName":"France","events":[{"notificationType":"START_OF_TRIAL","date":"2020-07-20"},{"notificationType":"START_OF_RECRUITMENT","date":"2020-07-23"},{"notificationType":"END_OF_RECRUITMENT","date":"2026-06-23"}]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"D1_Protocol 2024-513248-27-00","uuid":"2916f0cb-93a6-44f8-8ccd-cb6c2092df19","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":86598,"manualVersion":"6","systemVersion":"3"},{"title":"D1_Synopsis 2024-513248-27-00","uuid":"19ebbaab-c6bd-480c-9cd7-639b142a037f","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":86598,"manualVersion":"6","systemVersion":"3"},{"title":"2019-001209-26_Annexe 14 RCP Acide zoledronique_V1_20190509_ZOSTER","uuid":"fa628b2d-504f-40dd-b1d0-491cef774ad5","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":269627,"manualVersion":"1","systemVersion":"1"},{"title":"2019-001209-26_Annexe 15 RCP Denosumab V1_20211203_ZOSTER","uuid":"5d3139b4-0376-4d47-8bbe-1705025cdfbe","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":269628,"manualVersion":"1","systemVersion":"1"},{"title":"2019-001209-26_Informed consent patient recruitment procedure_20240422_ZOSTER","uuid":"5c339fe5-74d9-4c13-aeaa-3666b00d091c","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":217328,"manualVersion":"1","systemVersion":"1"},{"title":"L2_Information et Questionnaire des aidants","uuid":"9f89291d-aa1f-4513-9e07-a3dc9cf10750","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":217328,"manualVersion":"2","systemVersion":"2"},{"title":"L2_Questionnaire EQ-5D-5L","uuid":"6bafbc0b-c776-4e72-8934-ed432e4e09ca","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":217328,"manualVersion":"2","systemVersion":"2"},{"title":"L2_Carte patient","uuid":"8881af7b-4b15-4153-bc8c-61f6f8838706","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":217328,"manualVersion":"3","systemVersion":"2"},{"title":"L2_Questionnaire BPI","uuid":"a9c40e92-74cc-4b52-b8eb-167bf7ed8901","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":217328,"manualVersion":"3","systemVersion":"2"},{"title":"L1_SIS and ICF","uuid":"47313c3f-ebc3-41e8-854b-85cddcd63eab","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":217328,"manualVersion":"6","systemVersion":"2"}],"trialRegion":"EEA","trialRegionCode":1,"correctiveMeasures":[]}